Scarica l'app Stockscreener
235.28
2.32%
5.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$229.33
Aprire:
$231
Volume 24 ore:
172.90K
Relative Volume:
0.76
Capitalizzazione di mercato:
$4.71B
Reddito:
$274.48M
Utile/perdita netta:
$153.56M
Rapporto P/E:
31.90
EPS:
7.3755
Flusso di cassa netto:
$114.06M
1 W Prestazione:
+12.93%
1M Prestazione:
+1.46%
6M Prestazione:
+13.82%
1 anno Prestazione:
+130.95%
Intervallo 1D:
$228.65
$236.35
Intervallo di 1 settimana:
$209.38
$236.35
Portata 52W:
$98.89
$247.38
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
234.85 | 4.60B | 274.48M | 153.56M | 114.06M | 7.3755 |
VRTX
Vertex Pharmaceuticals Inc
|
437.30 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.04 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.30 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.32 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.14 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | BofA Securities | Buy |
| 2025-12-09 | Iniziato | Citigroup | Buy |
| 2025-04-10 | Iniziato | Stifel | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Ligand Pharmaceuticals Bets Big on Royalty Growth - TipRanks
XOMA Royalty amends merger agreement with Ligand Pharmaceuticals By Investing.com - Investing.com Canada
Ligand Pharmaceuticals Files 8-K Announcing Amendment No. 1 to Agreement and Plan of Merger with XOMA Royalty Corporation 10 - Minichart
XOMA Royalty Corp Announces SEC Filing for Merger Agreement with Ligand Pharmaceuticals - Minichart
XOMA Royalty amends merger agreement with Ligand Pharmaceuticals - Investing.com
Ligand Pharmaceuticals amends merger agreement with XOMA Royalty Corporation - Investing.com
XOMA Royalty Amends Ligand Merger Agreement, Adding Holding Company to Advance Acquisition - TradingView
XOMA Royalty (XOMA) adds new holding company to structure of Ligand acquisition - Stock Titan
Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company - TradingView
Ligand (NASDAQ: LGND) amends XOMA Royalty merger, adds Nevada holding company - Stock Titan
Stephens Investment Management Group LLC Cuts Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Isthmus Partners LLC Reduces Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals Live Share Prices and Trades. LGND.US Live Streaming Share Prices. - London South East
Orchestra BioMed Secures Ligand Funding for Pivotal Trials - MyChesCo
Ligand Pharmaceuticals Insider Sold Shares Worth $563,080, According to a Recent SEC Filing - Moomoo
Ligand Pharmaceuticals' (NASDAQ:LGND) Strong Earnings Are Of Good Quality - Yahoo Finance
Travere, Ligand Pharma announce FDA label expansion for Filspari - MSN
Ligand Pharmaceuticals director sells $563,079 in shares By Investing.com - Investing.com India
LGND director sells 2,501 shares after option exercise | LGND Insider Trading - Stock Titan
Ligand Pharmaceuticals director sells $563,079 in shares - Investing.com
Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million - MSN
TradingKey - TradingKey
Ligand Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
John Kozarich sells shares; LGND (NASDAQ: LGND) option exercise for 1,575 shares - Stock Titan
RBC Capital Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $262 - Moomoo
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2026 Earnings Call Transcript - Insider Monkey
Ligand-Xoma Deal Would Combine Two Royalty Aggregators -- WSJ - Moomoo
Kozarich files Form 144 to sell 459 shares (NASDAQ: LGND) - Stock Titan
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $262 - 富途牛牛
Ligand (LGND) Q1 2026 Earnings Call Transcript - The Globe and Mail
A Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta Termination - Yahoo Finance
State of New Jersey Common Pension Fund D Trims Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals’ Earnings Call Signals Scaled Royalty Push - TipRanks
LGND: 1Q:26 Results Highlight Breadth of Portfolio - Yahoo Finance
UBS Group AG Purchases 31,081 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Q1 2026 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
LGND Maintained by RBC Capital -- Price Target Raised to $262 - GuruFocus
Ligand (NASDAQ: LGND) lifts Q1 2026 royalties but books Pelthos fair value loss - Stock Titan
RBC Raises Price Target on Ligand Pharmaceuticals to $262 From $252, Keeps Outperform Rating - marketscreener.com
Ligand Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise - Moomoo
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $262 - Moomoo
Ligand Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Ligand (LGND) Completes $15M Investment in Orchestra BioMed - GuruFocus
MSN Money - MSN
Earnings call transcript: Ligand Pharmaceuticals Q1 2026 results miss forecasts - Investing.com Canada
Ligand Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ligand Pharmaceuticals Reports $32.4 Million in Revenue for Q1 2026 - geneonline.com
Ligand Pharmaceuticals Incorporated : First Quarter 2026 Earnings Webcast - marketscreener.com
Ligand: Q1 Earnings Snapshot - KTVB
Ligand holds $779M, keeps 2026 outlook with XOMA deal set for Q3 - Stock Titan
Ligand (LGND) Q1 2026 royalty revenue jumps 56% as guidance reaffirmed - Stock Titan
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ligand Pharmaceuticals Inc Azioni (LGND) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KOZARICH JOHN W | Director |
May 12 '26 |
Option Exercise |
69.51 |
459 |
31,905 |
42,245 |
| KOZARICH JOHN W | Director |
May 13 '26 |
Sale |
223.50 |
1,575 |
352,012 |
41,786 |
| KOZARICH JOHN W | Director |
May 01 '26 |
Sale |
231.80 |
467 |
108,251 |
41,786 |
| KOZARICH JOHN W | Director |
May 12 '26 |
Sale |
224.00 |
459 |
102,816 |
41,786 |
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):